Skip to main content

Month: May 2025

MARA Announces Bitcoin Production and Mining Operation Updates for April 2025

Energized Hash Rate Grew 5.5% to 57.3 EH/sIncreased BTC Holdings* to 48,237 BTC Fort Lauderdale, FL, May 05, 2025 (GLOBE NEWSWIRE) — MARA Holdings, Inc. (NASDAQ: MARA) (“MARA” or the “Company”), a vertically integrated digital energy and infrastructure company that leverages high-intensity compute, such as bitcoin (“bitcoin” or “BTC”) mining, to monetize excess energy and optimize power management, today published unaudited bitcoin production updates for April 2025. Management Commentary “In April, our production saw a 15% month-over-month decrease in blocks won, as global hashrate had its second largest monthly gain on record and mining difficulty grew 8% from March,” said Fred Thiel, MARA’s chairman and CEO. “Despite these headwinds, our energized hashrate...

Continue reading

Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

– Data reveal WTX-921 is efficacious in a mouse colitis model, resulting in reduced tissue damage and inflammatory cytokine production – – Findings offer a more detailed understanding of WTX-921’s anti-inflammatory impact on the immune landscape in the inflamed colon – WATERTOWN, Mass., May 05, 2025 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced a poster presentation further characterizing its conditionally-activated IL-10 INDUKINE molecule, WTX-921, at IMMUNOLOGY2025, the annual meeting of the American Association of Immunologists...

Continue reading

Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.

Builds upon Firefly’s recent acceptance into the NVIDIA Connect program Marks next major step toward building a proprietary foundation model of the human brain KENMORE, N.Y., May 05, 2025 (GLOBE NEWSWIRE) — Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announce its acquisition of Evoke Neuroscience, Inc. (“Evoke”), a medical device company developing and commercializing technologies to aid in the comprehensive assessment of brain health. The transaction marks another important step toward Firefly building a proprietary foundation model of the human brain using its FDA-cleared Brain Network Analytics (“BNA™”) technology. As...

Continue reading

Watsco Acquires Southern Ice Equipment Distributors

Leading Food-Service and Commercial Refrigeration Distributor in Sunbelt Markets MIAMI, May 05, 2025 (GLOBE NEWSWIRE) — Watsco, Inc. (NYSE: WSO) announced that it has completed the acquisition of Southern Ice Equipment Distributors as well as two other transactions completed thus far in 2025. Terms of the transactions were not disclosed. Founded in 1984 and based in Lafayette, Louisiana, Southern Ice is a leading distributor of food-service and commercial refrigeration equipment, parts and supplies, including products manufactured by Manitowoc Ice, a division of Pentair plc. The Company operates seven locations in key Sunbelt markets including Louisiana, Mississippi, Arkansas, Texas, New Mexico and Arizona. Southern Ice will operate under its existing name and under the direction of its current leadership team to provide continuity...

Continue reading

Vencora Expands Presence in Australia with Acquisition of Data Action

TORONTO, May 05, 2025 (GLOBE NEWSWIRE) — Vencora, a long-term acquirer of financial services technology companies, today announced that it has acquired Data Action (“DA”), a leading Australian provider of core and digital banking solutions and technology services. Today’s announcement marks Vencora’s first acquisition of an Australian-based banking technology company, and together with Vencora’s insurance technology business SSP, it greatly expands Vencora’s presence within the region. DA was founded in 1986 as a co-operative undertaking by eight local credit unions. Headquartered in Adelaide, South Australia, the company provides a strong suite of solutions to financial institutions nationwide. Today, DA is a leading banking platform provider for challenger banks that supports over five million customer accounts across Australia. “We...

Continue reading

Tyson Foods Reports Second Quarter 2025 Results

Strong Execution Drives Top and Adjusted Bottom-Line Gains SPRINGDALE, Ark., May 05, 2025 (GLOBE NEWSWIRE) — Tyson Foods, Inc. (NYSE: TSN), one of the world’s largest food companies and a recognized leader in protein with leading brands including Tyson, Jimmy Dean, Hillshire Farm, Ball Park, Wright, Aidells, ibp and State Fair, reported the following results:(in millions, except per share data) Second Quarter   Six Months Ended    2025       2024       2025       2024  Sales $ 13,074     $ 13,072     $ 26,697     $ 26,391                 Operating Income $ 100     $ 312     $ 680     $ 543  Adjusted1 Operating Income (non-GAAP) $ 515     $ 406     $ 1,174     $ 817                 Net Income Per Share Attributable to Tyson $ 0.02     $ 0.41     $ 1.03     $ 0.71  Adjusted1 Net Income Per Share Attributable...

Continue reading

Pershing Square to Invest $900 million to Acquire Nine Million Newly Issued Shares of Howard Hughes Holdings and Transform HHH Into a Diversified Holding Company

Pershing Square to Support HHH’s Strategic Expansion Through Investment, Advisory, and Other Resources HHH Will Operate as a Diversified Holding Company Seeking to Acquire Controlling Interests in High-Quality, Durable Growth Public and Private Companies Howard Hughes Corporation, HHH’s Real Estate Development Business and Principal Subsidiary, Will Continue as the Nation’s Leading Community Builder Pershing Square’s Primary Purchase of HHH Stock for $100.00 per Share Represents a 48% Premium to Friday’s Closing Price Pershing Square Will Now Own 46.9% of the Company Pershing Square’s Investment Materially Improves Howard Hughes’ Credit Profile and Strategic and Financial Flexibility THE WOODLANDS, Texas and NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) — Howard Hughes Holdings Inc. (NYSE: HHH) (the “Company,” “Howard Hughes” or “HHH”)...

Continue reading

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

—Q1 2025 ORLADEYO net revenue of $134.2 million (+51 percent y-o-y)— —Full year 2025 ORLADEYO revenue guidance increased to $580 million to $600 million— —Company now expects to be profitable for full year 2025, a year ahead of schedule— —Company pays down $75 million of debt; saves approximately $23.5 million over life of loan— —NDA submitted for ORLADEYO oral granules for children with HAE aged 2-11— —U.S. IND open for BCX17725 for Netherton syndrome— RESEARCH TRIANGLE PARK, N.C., May 05, 2025 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. “We started 2025 with another quarter of outstanding performance. ORLADEYO revenue growth was driven by moving ORLADEYO patients from free drug to paid at a much faster...

Continue reading

Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Total 1Q 2025 net product revenue of $121.5 million, representing 62% year-over-year growth AUVELITY® 1Q 2025 net product sales of $96.2 million, representing 80% year-over-year growth SUNOSI® 1Q 2025 net product revenue of $25.2 million, representing 17% year-over-year growth SYMBRAVO® approved for the acute treatment of migraine; commercial launch on track for June 2025 NDA for AXS-14 for the management of fibromyalgia submitted to the FDA Supplemental NDA submission for AXS-05 in Alzheimer’s disease agitation on track for 3Q 2025 NDA submission for AXS-12 for cataplexy in patients with narcolepsy anticipated in 2H 2025 Positive topline results of FOCUS Phase 3 trial of solriamfetol in ADHD announced Initiation of Phase 3 trial of solriamfetol in major depressive disorder with excessive daytime sleepiness anticipated in 2025 Positive...

Continue reading

TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance

First quarter 2025 BRIUMVI U.S. net revenue of $119.7 million Raises full year 2025 global net revenue target to approximately $575 million and raises full year BRIUMVI U.S. net revenue target to approximately $560 million Conference call to be held today, Monday, May 5, 2025, at 8:30 AM ET    NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2025, along with recent company developments and provided an update on 2025 revenue guidance. Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, stated, “2025 is off to a strong start, and I’m incredibly proud of the progress made thus far. Our performance in the first quarter, including BRIUMVI’s $119.7 million in U.S. net sales, demonstrates...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.